In dysmetabolic patients HOMA-IR and LAP showed the best accuracy in detecting MASLD. The possible use of lipid-based IR markers in stratifying the CV risk in patients with MASLD needs further validation in larger cohorts.
Stefano Romeo, Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, Francesco Malvestiti, Ruifang Li‐Gao, Rosellina Margherita Mancina, Marcus Alvarez, Kyla Gelev, Samantha Maurotti, Umberto Vespasiani‐Gentilucci, Frits R. Rosendaal, Julia Kozlitina, Päivi Pajukanta, François Pattou, Luca Valenti
Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, Francesco Malvestiti, Ruifang Li‐Gao, Rosellina Margherita Mancina, Marcus Alvarez, Kyla Gelev, Samantha Maurotti, Umberto Vespasiani‐Gentilucci, Frits R. Rosendaal, Julia Kozlitina, Päivi Pajukanta, François Pattou, Luca Valenti, Stefano Romeo
Koen C. van Son, L.C. te Nijenhuis-Noort, Sebastiaan C. Boone, Dennis O. Mook‐Kanamori, Adriaan G. Holleboom, Paul R. Roos, Hildo J. Lamb, Gabrielle Alblas, Minneke J. Coenraad, Frits R. Rosendaal, Renée de Mutsert, Maarten E. Tushuizen
Discussion(0)
No comments yet. Be the first to comment.